Navigation Links
Loxapine in Medical News

Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002

...art of that transaction, Alexza licensed to Symphony Allegro its Staccato loxapine program and its Staccato alprazolam program. Since that time, Alexza has...ed certain intellectual property rights to Staccato alprazolam and Staccato loxapine in connection with our Symphony Allegro arrangement and will not receive ma...

Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008

...ide $50 million of funding through Symphony Allegro, an affiliate of Symphony Capital, for additional clinical and nonclinical development of Staccato loxapine (AZ-004 and AZ-104) and Staccato alprazolam (AZ-002). Alexza continues to be primarily responsible for the development of these three product candidat...
Loxapine in Medical Technology

Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches

...l established Symphony Allegro, Inc., which is providing funding to Alexza to accelerate clinical and other related development activities of Staccato loxapine (AZ-004 and AZ-104) and Staccato alprazolam (AZ-002). Alexza has granted a license to certain intellectual property rights for the selected product c...

Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial

...s a potentially important new drug candidate for treating acute agitation. loxapine is a well established antipsychotic and the Staccato system enables patient...to accelerate clinical and other related development activities of Staccato loxapine (AZ-004 and AZ-104) and Staccato alprazolam (AZ-002). Alexza has granted a...

Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients

...resident, Research and Development. "We believe that the ability to provide loxapine via our Staccato technology, thus combining a drug with a well-established ...to accelerate clinical and other related development activities of Staccato loxapine (AZ-004 and AZ-104) and Staccato alprazolam (AZ-002). Alexza has granted a ...

Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates

...t the patients remained in the clinic. Alexza's original IND for Staccato loxapine was filed with the Division of Neuropharmacological Drug Products of the FD...ducts, or DPP, and the Division of Neurology Products, or DNP. The Staccato loxapine IND was transferred to the DPP, as the AZ-004 development program is for a ...

Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)

...ive nature and rapid pharmacokinetic (PK) properties resulting from inhaled loxapine administration via the Staccato system have the potential to make AZ-004 a ...e end of September 2008. The Company believes that the unique delivery of loxapine via the Staccato system will provide rapid onset of drug effect, as measure...

Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting

...FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that it will present results of its Phase 2a clinical trial of Staccato(R) loxapine (AZ-104) for the treatment of migraine headache at the 50th Annual Scientific Meeting of the American Headache Society, which being held at the Marrio...

Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation

...er designed to generate and deliver excipient-free loxapine aerosol for deep lung delivery that results in IV-... The Company believes that the unique delivery of loxapine via the Staccato system will provide rapid onset o...d other related development activities of Staccato loxapine (AZ-004 and AZ-104) and Staccato alprazolam (AZ-00...

Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting

...tion annual meeting the results of a Phase 2a clinical trial of Staccato(R) loxapine (AZ-004) for the treatment of acute agitation in schizophrenic patients. The poster presentation, "Inhaled loxapine Rapidly Improves Acute Agitation in Schizophrenic Patients" (Presentation N...

Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache

...ient-free drug aerosol for deep lung delivery that results in IV-like pharmacokinetics. In a Phase 1 dose-escalation clinical trial, doses of Staccato loxapine ranging from 0.625 to 10 mg were generally well tolerated and there were no serious adverse events. Across all doses, pharmacokinetic analyses reveale...

Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients

...stem with loxapine, a drug belonging to the class of compounds known as antipsychotics. In a Phase 1 dose-escalation clinical trial, doses of Staccato loxapine ranging from 0.625 to 10 mg were generally well tolerated and there were no serious adverse events. Across all doses, pharmacokinetic analyses reveale...
Loxapine in Biological Technology

Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)

...ive nature and rapid pharmacokinetic (PK) properties resulting from inhaled loxapine administration via the Staccato system have the potential to make AZ-004 a ... schizophrenic patients. The Company believes that the unique delivery of loxapine via the Staccato system will provide rapid onset of drug effect, as measure...
Other Tags
(Date:2/26/2015)... SpendWell Health, an online marketplace for ... first customer today, opening its doors to Cambia ... , SpendWell delivers the next generation of online ... transparency with e-commerce. SpendWell’s unique platform shows actual ... services and allows shoppers to buy those services ...
(Date:2/26/2015)... February 26, 2015 Participants in ... What’s Working? What’s Not? What’s New? ,” will ... programs to achieve strong outcomes for duals-plan members ... happening in the implementation phase of programs for ... made? Which ones need to be implemented in ...
(Date:2/26/2015)... Falls Church, VA (PRWEB) February 26, 2015 ... Medical Devices:, Understanding the FDA’s Position and Best ... April 14-15, 2015 – Bethesda, MD, http://www.fdanews.com/SoftwareAndCybersecurity ... renowned expert Fubin Wu — has been specifically ... to achieve compliance and effectively assure medical device ...
(Date:2/26/2015)... February 26, 2015 Eating disorders ... and young adulthood. In response to emerging research ... in support of National Eating Disorders Awareness Week, ... presents new evidence-based recommendations for the medical management ... adults, including a new approach to assessing the ...
(Date:2/26/2015)... February 26, 2015 Body Well Therapy, a ... years of delivering high quality mobile massage services ... other regions across the United States. The company has experienced ... pivotal year as it sets its sights on additional major ... chair massage services. , “We’ve come a long way since ...
Breaking Medicine News(10 mins):Health News:SpendWell Launches New Online Health Care Marketplace to Large Employer Group 2Health News:SpendWell Launches New Online Health Care Marketplace to Large Employer Group 3Health News:Upcoming AIS Virtual Conference Will Explain What Is and Is Not Working in Medicare-Medicaid Dual Eligibles Programs 2Health News:FDAnews New Workshop — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, April 14-15 2Health News:FDAnews New Workshop — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, April 14-15 3Health News:FDAnews New Workshop — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, April 14-15 4Health News:SAHM: Medical Providers Have Vital Lead Role in Diagnosing, Treating Restrictive Eating Disorders in Adolescents and Young Adults 2Health News:SAHM: Medical Providers Have Vital Lead Role in Diagnosing, Treating Restrictive Eating Disorders in Adolescents and Young Adults 3Health News:Body Well Therapy Celebrates 10 Years of Quality Mobile Massage Services 2Health News:Body Well Therapy Celebrates 10 Years of Quality Mobile Massage Services 3
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, North Carolina , ... in sein 35. Jahr als spezialisiertes Logistikunternehmen ... seine Position als einzige klinische Logistikfirma (Clinical ... soll. Die Kernbotschaft der neuen Kampagne lautet ... Protokollen und Lieferungen. Foto: ...
(Date:2/5/2015)... Jan. 27, 2015   Marvin Test ... deployed, innovative test solutions for military, aerospace, ... of its TS-323 GENASYS Test Platform ... (LMSSC). GENASYS is a high-performance PXI-based system ... applications that require performance functional testing. GENASYS ...
(Date:2/5/2015)... 2015  It is gratifying to see that the ... genomic science as a means to better understand human ... I was honored to participate in today,s White House ... Since the 1980s my teams have ... first sequenced genome of a free living organism, the ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2
Other Contents